Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action
Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...
Eisai submitted a marketing authorization application for Leqembi, the Alzheimer’s drug jointly developed with Biogen, to the European Medicines Agency, the company announced late Tuesday afternoon.
Anavex Life Sciences (AVXL) lost ~18% in the premarket on Wednesday after the company announced that it withdrew the marketing authorization application for its Alzheimer’s candidate, blarcamesine, in ...
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results